Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program
Brendon L. Neuen, Toshiaki Ohkuma, Bruce Neal, David R. Matthews, Dick de Zeeuw, Kenneth W. Mahaffey, Greg Fulcher, Jaime D. Blais, Qiang Li, Meg Jardine, Vlado Perkovic, David C. Wheeler
Topics & Concepts
CanagliflozinMedicineKidney diseaseRenal functionInternal medicineDiabetes mellitusAlbuminuriaType 2 diabetesCreatininePopulationRelative riskPost-hoc analysisPlaceboConfidence intervalEndocrinologyPathologyAlternative medicineEnvironmental healthDiabetes Treatment and ManagementDiabetes Management and ResearchPancreatic function and diabetes